Naomi Haas, M.D.

Abramson Cancer Center at Penn Medicine

Director, Prostate and Kidney Cancer Program 

University of Pennsylvania

Professor of Medicine

Naomi Haas, MD | Kidney Cancer Research Consortium
Dr. Naomi Haas, MD, stands at the forefront of kidney and prostate cancer clinical research as the Director of Kidney and Prostate Cancer Clinical Research at Penn Medicine and an Associate Professor of Medicine at the Hospital of the University of Pennsylvania. Her international reputation as an expert in the design and execution of adjuvant clinical trials for kidney cancer, coupled with her national prominence in prostate and kidney cancer therapeutics, underscores her significant contributions to advancing the field.


Educational Background:

Dr. Haas’ academic journey is marked by her dedication to medicine and oncology. Attaining her medical degree laid the foundation for her illustrious career, and her subsequent training has equipped her with the knowledge and skills necessary to navigate the complexities of kidney and prostate cancer.


Education & Training

Medical School
Northeastern Ohio University – College of Medicine

Abington Memorial Hospital

Fox Chase Cancer Center


Board Memberships:

NCI Genitourinary Steering Committee


Professional Accomplishments:

In her role as the institutional principal investigator for the HCRN study GU16-260, Dr. Haas leads groundbreaking research on the front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma. Her involvement in GU16-257, focused on neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing, further showcases her commitment to advancing innovative treatment approaches.

Research Focus:

Dr. Haas’ research interests encompass a spectrum of early-phase cancer clinical trials, with a primary focus on kidney and prostate cancer. Her work extends to the study of emerging treatment modalities, including CAR T-Cell therapy, immune checkpoint inhibition, angiogenesis, and epigenetics. Notably, her early exposure to retrotransposons, a unique genetic component, during her time in a basic science lab at Fox Chase Cancer Center adds a distinctive dimension to her research expertise. Dr. Haas adopts a multifaceted approach, exploring diverse treatment avenues and incorporating cutting-edge technologies. Her involvement in investigating retrotransposons showcases a commitment to delving into genetic intricacies, highlighting her dedication to understanding cancer at both molecular and clinical levels.


Leadership and Impact:

Dr. Haas’ role as the Director of Kidney and Prostate Cancer Clinical Research at Penn Medicine positions her as a driving force in shaping the institution’s research landscape. Her leadership fosters a dynamic environment where innovative ideas flourish, contributing to the institution’s reputation as a hub of groundbreaking research and patient care. Dr. Haas’ tireless efforts in advancing the understanding and treatment of kidney and prostate cancers solidify her as a leader in the field, with a lasting impact on both Penn Medicine and the broader realm of oncology.

Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Hans Hammers

UT Southwestern

Eric Jonasch, M.D. | Kidney Cancer Research Consortium

Eric Jonasch

MD Anderson

David McDermott, MD | Kidney Cancer Research Consortium

David McDermott

Beth Israel

Brian Rini, MD | Kidney Cancer Research Consortium

Brian Rini

Vanderbilt University

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium

Ulka Vaishampayan

University of Michigan